Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

AstraZeneca has completed the resurrection of its anifrolumab drug for systemic ... Now given the brand name Saphnelo, the antibody is the first type I interferon receptor antagonist to be ...

A newer lupus drug can protect patients from long-term organ damage Anifrolumab (Saphnelo) lowered the risk of long-term organ damage progression by about 60% The drug received federal approval in ...

Saphnelo (Anifrolumab) is instrumental in addressing autoimmune conditions by targeting and inhibiting the type I interferon receptor. Since this receptor is frequently overactive in autoimmune ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...